Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: Oncogenic and immunological functions of USP35 in pan-cancer and its potential as a biomarker in kidney clear cell carcinoma

Fig. 6

USP35 related prognostic analysis in KIRC. A Univariate and multivariate Cox regression analysis for USP35 expression and other clinical factors in KIRC. B Non-linear relationship between USP35 expression and hazard ratio (HR), showing increased risk with higher USP35 expression levels. C ROC curve analysis of USP35 expression predicting 1-year, 5-year, and 10-year survival in KIRC patients. D Meta-analysis showing the association of USP35 expression with hazard ratios across multiple datasets. E–G Kaplan–Meier survival curves showing the correlation between high and low USP35 expression with disease-specific survival (E), progression-free interval (F), and overall survival (G) in KIRC. H-J Stratified analysis of USP35 expression into quartiles (Q1-Q4), showing significant differences in disease-specific survival (H), progression-free interval (I), and overall survival (J)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us